ASH 2019 | LEGEND-2 and CARTITUDE-1: anti-BCMA CAR-T for myeloma
Yi Lin
• 6 Dec 2019
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, covers the LEGEND-2 (NCT03090659) and CARTITUDE-1 (NCT03548207) of an anti-BCMA CAR-T for multiple myeloma. This is a structurally differentiated CAR T-cell therapy containing a 4-1BB costimulatory domain and 2 BCMA-targeting single-domain antibodies, named LCAR-B38M and JNJ-4528. She goes onto discuss future approaches, which are targeting BCMA as well as other antigens including CD19 or CD38. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
